<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6934327</article-id><article-id pub-id-type="pmid">31765414</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0007829</article-id><article-id pub-id-type="publisher-id">PNTD-D-19-00427</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Fevers</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Fevers</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Thrombocytopenia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Asia</subject><subj-group><subject>China</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Regression Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Regression Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Central Nervous System</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Central Nervous System</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>A nomogram to predict mortality in patients with severe fever with thrombocytopenia syndrome at the early stage&#x02014;A multicenter study in China</article-title><alt-title alt-title-type="running-head">A nomogram to predict mortality of SFTS at the early stage</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lin</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Gang</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Yi</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Zhenghua</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ling</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wei</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Rui</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Di</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Jing</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yongxiang</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Xiaoli</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Li</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Yang</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yuanni</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Qiang</surname><given-names>Chunqian</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Duan</surname><given-names>Jianping</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Yanli</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ying</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yanan</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Chong</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ge</surname><given-names>Ziruo</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xingwang</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6481-4781</contrib-id><name><surname>Chen</surname><given-names>Zhihai</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3401-1280</contrib-id><name><surname>Fan</surname><given-names>Tianli</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9991-7892</contrib-id><name><surname>Li</surname><given-names>Wei</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff009"><sup>9</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Statistics Room, Beijing Ditan Hospital, Capital Medical University, Beijing, China</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Infectious Diseases, Dandong Infectious Disease Hospital, Dandong, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Infectious Disease, Taian City Central Hospital, Taian, China</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Infectious Disease, Yantai City Hospital for Infectious Disease, Yantai, China</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Infectious Disease, Qing Dao No. 6 People&#x02019;s Hospital, Qingdao, China</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Graduate School of Capital Medical University, Beijing, China</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Interventional Therapy Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Makepeace</surname><given-names>Benjamin L</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Liverpool, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="other" id="econtrib001"><p>&#x02021; These authors contributed equally to this work and share first authorship.</p></fn><corresp id="cor001">* E-mail: <email>chenzhihai0001@126.com</email> (ZC); <email>15666687786@163.com</email> (TF); <email>vision988@126.com</email> (WL)</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2019</year></pub-date><volume>13</volume><issue>11</issue><elocation-id>e0007829</elocation-id><history><date date-type="received"><day>12</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>4</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Wang et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Wang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pntd.0007829.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Severe fever with thrombocytopenia syndrome (SFTS) caused by the SFTS virus is an emerging infectious disease that was first identified in the rural areas of China in 2011. Severe cases often result in death due to multiple organ failure. To date, there are still numerous problems remain unresolved in SFTS, including unclear pathogenesis, lack of specific treatment, and no effective vaccines available.</p></sec><sec id="sec002"><title>Aim</title><p>To analyze the clinical information of patients with early-stage SFTS and to establish a nomogram for the mortality risk.</p></sec><sec id="sec003"><title>Methods</title><p>Between April 2011 and December 2018, data on consecutive patients who were diagnosed with SFTS were prospectively collected from five medical centers distributed in central and northeastern China. Multivariable Cox analyses were used to identify the factors independently associated with mortality. A nomogram for mortality was established using those factors.</p></sec><sec id="sec004"><title>Results</title><p>During the study period, 429 consecutive patients were diagnosed with SFTS at the early stage of the disease (within 7 days of fever), among whom 69 (16.1%) died within 28 days. The multivariable Cox proportional hazard regression analysis showed that low lymphocyte percentage, early-stage encephalopathy, and elevated concentration of serum LDH and BUN were independent risk factors for fatal outcomes. Received-operating characteristic curves for 7-, 14-, and 28-days survival had AUCs of 0.944 (95% CI: 0.920&#x02013;0.968), 0.924 (95% CI: 0.896&#x02013;0.953), and 0.924 (95% CI: 0.895&#x02013;0.952), respectively. Among low-risk patients, 6 patients died (2.2%). Among moderate-risk patients, 25 patients died (24.0%, hazard ratio (HR) = 11.957). Among high-risk patients, the mortality rate was 69.1% (HR = 57.768).</p></sec><sec id="sec005"><title>Conclusion</title><p>We established a simple and practical clinical scoring system, through which we can identify critically ill patients and provide intensive medical intervention for patients as soon as possible to reduce mortality.</p></sec></abstract><abstract abstract-type="summary"><title>Author summary</title><p>We established a SFTS nomogram scoring system, which is the first nomogram for this disease. According to this nomogram, patients were divided into three levels of mortality risk: low, moderate, and high. This scoring system is helpful to identify critically ill patients, allowing for early intervention and intensive care, which may contribute to reducing the mortality of SFTS.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Special Fund For High-level Talents in Beijing Health System Project</institution></funding-source><award-id>2011-3-079</award-id></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100009331</institution-id><institution>Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support</institution></institution-wrap></funding-source><award-id>XMLX201502 and XMLX201602</award-id></award-group><award-group id="award003"><funding-source><institution>National Science and Technology Major Project of China</institution></funding-source><award-id>2018ZX09711003</award-id></award-group><funding-statement>This study was supported by the Special Fund For High-level Talents in Beijing Health System Project (2011-3-079), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (XMLX201502 and XMLX201602) and the National Science and Technology Major Project of China (2018ZX09711003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="5"/><page-count count="17"/></counts><custom-meta-group><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2019-12-27</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript.</p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>Severe fever with thrombocytopenia syndrome (SFTS) caused by the SFTS virus (SFTSV) is an emerging infectious disease that was first identified in the rural areas of China in 2011 [<xref rid="pntd.0007829.ref001" ref-type="bibr">1</xref>]. The patients are all from the hilly areas of central and northeastern China, and are mostly farmers working in the endemic areas. Most of the cases occur between April and October and Haemaphysalis longicornis is considered the most likely transmission vector [<xref rid="pntd.0007829.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pntd.0007829.ref004" ref-type="bibr">4</xref>]. There were also reports of clustered cases and outbreaks of nosocomial infections [<xref rid="pntd.0007829.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0007829.ref006" ref-type="bibr">6</xref>], indicating that except for the tick bite, there is a potential risk of human-to-human transmission [<xref rid="pntd.0007829.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pntd.0007829.ref009" ref-type="bibr">9</xref>]. The major clinical manifestations of SFTS are fever, fatigue, thrombocytopenia and leucopenia, usually accompanied with myocardium impairment and elevated liver enzymes. Severe cases often die from multi-organ failure and the mortality rate of SFTS is 11.2%-30% [<xref rid="pntd.0007829.ref001" ref-type="bibr">1</xref>,<xref rid="pntd.0007829.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pntd.0007829.ref012" ref-type="bibr">12</xref>].</p><p>The disease is fairly broadly distributed in China, is tick-borne, and is epidemics in more than 20 provinces [<xref rid="pntd.0007829.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0007829.ref008" ref-type="bibr">8</xref>] and with increasing numbers of cases each year [<xref rid="pntd.0007829.ref013" ref-type="bibr">13</xref>]. Since the identification of the SFTSV in 2011, all patients are mandatorily reported by doctors within 24 h of diagnosis to the China Information System for Diseases Control and Prevention (CISDCP). In addition to its prevalence in rural area of central and northeastern China, this disease is widely distributed in South Korea [<xref rid="pntd.0007829.ref014" ref-type="bibr">14</xref>] and Japan [<xref rid="pntd.0007829.ref015" ref-type="bibr">15</xref>], two neighboring countries of China. In addition, other newly emerged phleboviruses were isolated from patients in USA in 2012, including the Heartland virus, a new phlebovirus, which is genetically similar to SFTSV [<xref rid="pntd.0007829.ref016" ref-type="bibr">16</xref>]. In 2011&#x02013;2016, a total of 5360 laboratory-confirmed patients were reported to the CISDCP. Annual patient numbers increased yearly and the numbers of affected counties increased sharply from 98 to 167 from 2011 to 2016 [<xref rid="pntd.0007829.ref017" ref-type="bibr">17</xref>]. The scope of the disease is expanding, with China being the hardest hit country and the mortality rate remains high.</p><p>The management of SFTS still faces issues such as unclear pathogenesis, lack of specific treatment, and no approved vaccines. The clinical symptoms of SFTS are non-specific and often need to be differentiated from human anaplasmosis and hemorrhagic fever with renal syndrome (HFRS) caused by hantavirus, since those two diseases are also found in the same geographical areas [<xref rid="pntd.0007829.ref001" ref-type="bibr">1</xref>]. Furthermore, laboratory diagnosis needs to be confirmed by the Centers for Disease Control and Prevention (CDC). In addition, there is still no consensus on the staging and classification of SFTS and, so far, there is no specific antiviral therapy. Therefore, identifying risk factors for death of SFTS can be helpful for further understanding of the viral pathogenesis and revealing the cause of death. Early identification of critically ill patients is very important to carry out symptomatic treatments to reduce the mortality rate. Therefore, there is an urgent need for establishing a death risk predictive scoring system, assessing the severity of illness, and predicting the risk of death in order to take effective public health measures to control the epidemic and to recognize which patients require early interventions. Public health measures could eventually include better education for better recognition of the disease by front-line physicians.</p><p>In the present prospective cohort study, we analyzed the clinical information of patients with SFTS at the early stage of the disease. We compared the data between the survival and mortality groups using univariable and multivariable Cox regression analyses in order to screen for significant critical early-stage factors related to death. Based on this analysis, we established a SFTS nomogram scoring system, which is intuitional, fast, practical, and operable [<xref rid="pntd.0007829.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0007829.ref019" ref-type="bibr">19</xref>], and is the first nomogram for this disease. Using this scoring system, we divided the patients into three levels of mortality risk: low, moderate, and high. This nomogram can identify critically ill patients at the early stage and could allow mortality reduction.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Patients and methods</title><sec id="sec008"><title>Patients</title><p>Between April 2011 and December 2018, data on consecutive patients who presented with acute fever (temperature &#x0003e;37.5&#x000b0;C for over 24 h) and thrombocytopenia (Platelet count &#x0003c;100&#x000d7;10<sup>9</sup> /L) were prospectively collected from the five medical centers distributed in central and northeastern China: Beijing Ditan Hospital, Dandong Infectious Disease Hospital, Taian City Central Hospital, Qing Dao No. 6 People&#x02019;s Hospital, and Yantai City Hospital for Infectious Disease. In total we enrolled 967 patients with clinical manifestation of fever accompanied by thrombocytopenia. Among them, 695 were patients diagnosed with SFTS, among whom 429 patients visited the hospitals at the early-stage (within 7 days from disease onset), which were the subjects of this study. This study was approved by the local Ethics Committee of the lead center, Beijing Ditan Hospital, Capital Medical University (number 2014&#x02013;003) and complied with the principles of the Declaration of Helsinki. Informed consent was obtained from all patients or their immediate relatives for sample and data collection and their use for research.</p><p>Patients diagnosed with SFTS were included in the study. The diagnosis of SFTS was confirmed by: 1) acute fever (temperature &#x0003e;37.5 &#x000b0;C for over 24 h) with thrombocytopenia (platelet count &#x0003c;100&#x000d7;10<sup>9</sup> /L); and 2) laboratory-confirmed SFTSV infection by detection of viral RNA (fluorescent probe PCR, BGI-GBI, Beijing, China), and/or virus-specific IgM antibody in the peripheral blood (ELISA, Zhongshan Bio-Tech CO., LTD, Guangdong, China) [<xref rid="pntd.0007829.ref020" ref-type="bibr">20</xref>]. Those two tests are routinely used for the diagnosis of SFTS in China. Routine validation is carried out using samples sent by the China Information System for Diseases Control and Prevention. The exclusion criteria were: 1) laboratory-confirmed other pathogen infection including Platts and Mori rickettsia, Orientia tsutsugamushi, Hantavirus, etc.; or 2) history of acute or chronic blood system diseases.</p></sec><sec id="sec009"><title>Treatment</title><p>All patients were given systemic support treatment, including infusion of blood products, granulocyte colony-stimulating factor (G-CSF), and Chinese traditional medicine. For patients with severe SFTS, glucocorticoid and/or hemodialysis were performed. All the patients received supportive measures, including rest, nutritional support, and electrolyte balance maintenance.</p></sec><sec id="sec010"><title>Data collection and definitions</title><p>Demographic and clinicopathological data were collected. Blood samples were collected on admission and throughout the disease course. For clinical data collection, we designed a medical record form and database in Epidata (Centers for Disease Control, Atlanta, GA, USA) that contains information of epidemiologic, clinical manifestations, physical examinations, and laboratory parameters. Demographic factors and date of onset were included. All data were entered by trained study staffs. Patients who discontinued therapy or were discharged from hospital because of personal reasons were followed till 28 days from disease onset time. The primary outcome was 28 days all-caused death.</p><p>The date of disease onset was defined as the day fever was noticed (self-reported). Early stage SFTS was defined as within 7 days from disease onset. Encephalopathy was defined as an altered mental status that persisted for more than 24 h, including lethargy, irritability, or a change in personality and behavior [<xref rid="pntd.0007829.ref021" ref-type="bibr">21</xref>]. Severe SFTS was defined as SFTS combined with multiple organ failure. Death was defined as death from any cause.</p></sec><sec id="sec011"><title>Statistical analysis</title><p>All statistical analyses were conducted with SPSS 19.0 (IBM, Armonk, NY, USA). Continuous variables are presented as mean &#x000b1; standard deviation or medians with interquartile ranges, while categorical variables are presented as frequencies or percentages of events. The two-sample t test or Mann-Whitney U test was used to determine the relationship between the survival and mortality for continuous data. The Pearson chi-square and Fisher&#x02019;s exact tests were used to compare differences in proportion between groups, as appropriate. Independent risk factors were identified by univariable and multivariable Cox regression analyses for predicting mortality.</p><p>A nomogram was formulated based on the results of the multivariable Cox regression analyses. The regression coefficient of different variables in the Cox regression equation and the extreme difference of the variables were used to calculate the product of the regression coefficient and the range of the different variables. Assuming that the largest product variable is 10 points, and assuming that the variable is a reference variable, the score corresponding to each unit of the variable could be calculated according to the range. The other variables were multiplied by the score corresponding to each unit of the reference variable according to the ratio of the regression coefficient to the regression coefficient of the reference variable, and the score corresponding to each unit of the variable was calculated. After calculating the score for each variable, the nomogram was formulated using the nomogram function of the RMS packages [<xref rid="pntd.0007829.ref022" ref-type="bibr">22</xref>] in R version 3.0.2 (The R Project for Statistical Computing, <ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">www.r-project.org</ext-link>).</p><p>The performance of the nomogram was evaluated by the concordance index (C-index). The maximum C-index value is 1.0, which indicates a perfect prediction model, whereas 0.5 indicates a random chance to correctly predict outcome by the model. The model was validated using bootstrapped resampling to quantify any overfitting. The calibration curve for the nomogram used 1000 repeated samples to obtain the corresponding actual incidence rate and 95% confidence interval (CI) at different probability levels to evaluate the consistency of model prediction. Bootstrap sampling was performed using the RMS packages in R version 3.0.2 (The R Project for Statistical Computing, <ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">www.r-project.org</ext-link>). Calibration curves of the nomogram for 7-, 14-, and 28-days were applied to assess the agreement between predicted and observed survival. Clinical survival outcomes were assessed by the Kaplan-Meier analysis and prognostic groups were compared by the log-rank test. The X-tile software package [<xref rid="pntd.0007829.ref023" ref-type="bibr">23</xref>] was used to search the cut-off value of nomogram points for grading death risk. All statistical tests were two-sided with a statistical significance level set at p values of &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><sec id="sec013"><title>Demographic and clinical characteristics of the patients with SFTS</title><p>During the study period, 429 consecutive patients were diagnosed with SFTS at the early stage of the disease (within 7 days of fever), among whom 69 died within 28 days. The mortality rate was 16.1%. The survival group included 201 women (46.9%) and 228 men (53.2%), while the mortality group included 26 women (37.7%) and 43 men (62.3%). There was no significant sex difference between the two groups. The mean age of all patients was 60.8&#x000b1;12.1 years. Notably, the mean age in patients who died was significantly higher than in those who survived (68.3 vs. 59.3; p &#x0003c; 0.05) (<xref rid="pntd.0007829.t001" ref-type="table">Table 1</xref>). Most of the cases occurred between May and October during the year. The patients were all from the hilly areas of central and northeast China, and were mostly farmers working in the endemic areas.</p><table-wrap id="pntd.0007829.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.t001</object-id><label>Table 1</label><caption><title>Comparison of gender, age, clinical symptoms, and laboratory parameters in the survival and mortality groups.</title></caption><alternatives><graphic id="pntd.0007829.t001g" xlink:href="pntd.0007829.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">All<break/>(n = 429)</th><th align="left" rowspan="1" colspan="1">Survival<break/>(n = 360)</th><th align="left" rowspan="1" colspan="1">Fatal<break/>(n = 69)</th><th align="left" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Sex, n (%)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" rowspan="1" colspan="1">228 (53.2)</td><td align="left" rowspan="1" colspan="1">185 (51.4)</td><td align="left" rowspan="1" colspan="1">43 (62.3)</td><td align="char" char="." rowspan="1" colspan="1">0.096</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" rowspan="1" colspan="1">201 (46.9)</td><td align="left" rowspan="1" colspan="1">175 (48.6)</td><td align="left" colspan="2" rowspan="1">26 (37.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years)</bold>
<xref ref-type="table-fn" rid="t001fn002"><sup>&#x000a7;</sup></xref></td><td align="left" rowspan="1" colspan="1">60.8&#x000b1;12.1</td><td align="left" rowspan="1" colspan="1">59.3&#x000b1;11.7</td><td align="left" rowspan="1" colspan="1">68.3&#x000b1;11.0</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Clinical symptoms, n (%)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chills</td><td align="left" rowspan="1" colspan="1">152 (35.4)</td><td align="left" rowspan="1" colspan="1">128 (35.6)</td><td align="left" rowspan="1" colspan="1">24 (34.8)</td><td align="char" char="." rowspan="1" colspan="1">0.902</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache <xref ref-type="table-fn" rid="t001fn002"><sup>&#x000a7;</sup></xref></td><td align="left" rowspan="1" colspan="1">125 (29.1)</td><td align="left" rowspan="1" colspan="1">115 (31.9)</td><td align="left" rowspan="1" colspan="1">10 (14.5)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Dizziness</td><td align="left" rowspan="1" colspan="1">121 (28.2)</td><td align="left" rowspan="1" colspan="1">108 (30.0)</td><td align="left" rowspan="1" colspan="1">13 (18.8)</td><td align="char" char="." rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" rowspan="1" colspan="1">Myalgia</td><td align="left" rowspan="1" colspan="1">178 (41.5)</td><td align="left" rowspan="1" colspan="1">153 (42.5)</td><td align="left" rowspan="1" colspan="1">25 (36.2)</td><td align="char" char="." rowspan="1" colspan="1">0.333</td></tr><tr><td align="left" rowspan="1" colspan="1">Anorexia</td><td align="left" rowspan="1" colspan="1">322 (75.1)</td><td align="left" rowspan="1" colspan="1">274 (76.1)</td><td align="left" rowspan="1" colspan="1">48 (69.6)</td><td align="char" char="." rowspan="1" colspan="1">0.250</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="left" rowspan="1" colspan="1">200 (46.6)</td><td align="left" rowspan="1" colspan="1">174 (48.3)</td><td align="left" rowspan="1" colspan="1">26 (37.7)</td><td align="char" char="." rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="left" rowspan="1" colspan="1">70 (16.3)</td><td align="left" rowspan="1" colspan="1">57 (15.8)</td><td align="left" rowspan="1" colspan="1">13 (18.8)</td><td align="char" char="." rowspan="1" colspan="1">0.536</td></tr><tr><td align="left" rowspan="1" colspan="1">Bloating</td><td align="left" rowspan="1" colspan="1">11 (2.6)</td><td align="left" rowspan="1" colspan="1">10 (2.8)</td><td align="left" rowspan="1" colspan="1">1 (1.5)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td align="left" rowspan="1" colspan="1">81 (18.9)</td><td align="left" rowspan="1" colspan="1">67 (18.6)</td><td align="left" rowspan="1" colspan="1">14 (20.3)</td><td align="char" char="." rowspan="1" colspan="1">0.744</td></tr><tr><td align="left" rowspan="1" colspan="1">Cough</td><td align="left" rowspan="1" colspan="1">75 (17.5)</td><td align="left" rowspan="1" colspan="1">64 (17.8)</td><td align="left" rowspan="1" colspan="1">11 (15.9)</td><td align="char" char="." rowspan="1" colspan="1">0.713</td></tr><tr><td align="left" rowspan="1" colspan="1">Sputum</td><td align="left" rowspan="1" colspan="1">49 (11.4)</td><td align="left" rowspan="1" colspan="1">42 (11.7)</td><td align="left" rowspan="1" colspan="1">7 (10.1)</td><td align="char" char="." rowspan="1" colspan="1">0.716</td></tr><tr><td align="left" rowspan="1" colspan="1">Chest distress</td><td align="left" rowspan="1" colspan="1">33 (7.7)</td><td align="left" rowspan="1" colspan="1">30 (8.3)</td><td align="left" rowspan="1" colspan="1">3 (4.4)</td><td align="char" char="." rowspan="1" colspan="1">0.255</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypourocrinia</td><td align="left" rowspan="1" colspan="1">34 (7.9)</td><td align="left" rowspan="1" colspan="1">31 (8.6)</td><td align="left" rowspan="1" colspan="1">3 (4.3)</td><td align="char" char="." rowspan="1" colspan="1">0.230</td></tr><tr><td align="left" rowspan="1" colspan="1">Encephalopathy <xref ref-type="table-fn" rid="t001fn002"><sup>&#x000a7;</sup></xref></td><td align="left" rowspan="1" colspan="1">109 (25.4)</td><td align="left" rowspan="1" colspan="1">52 (14.4)</td><td align="left" rowspan="1" colspan="1">57 (82.6)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Flush</td><td align="left" rowspan="1" colspan="1">83 (19.4)</td><td align="left" rowspan="1" colspan="1">71 (19.7)</td><td align="left" rowspan="1" colspan="1">12 (17.4)</td><td align="char" char="." rowspan="1" colspan="1">0.653</td></tr><tr><td align="left" rowspan="1" colspan="1">Pharyngeal hyperemia</td><td align="left" rowspan="1" colspan="1">141 (32.9)</td><td align="left" rowspan="1" colspan="1">120 (33.3)</td><td align="left" rowspan="1" colspan="1">21 (30.4)</td><td align="char" char="." rowspan="1" colspan="1">0.639</td></tr><tr><td align="left" rowspan="1" colspan="1">Petechia/Ecchymosis</td><td align="left" rowspan="1" colspan="1">37 (8.6)</td><td align="left" rowspan="1" colspan="1">28 (7.8)</td><td align="left" rowspan="1" colspan="1">9 (13.0)</td><td align="char" char="." rowspan="1" colspan="1">0.153</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphadenopathy</td><td align="left" rowspan="1" colspan="1">101 (23.5)</td><td align="left" rowspan="1" colspan="1">83 (23.1)</td><td align="left" rowspan="1" colspan="1">18 (26.1)</td><td align="char" char="." rowspan="1" colspan="1">0.587</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatosplenomegaly</td><td align="left" rowspan="1" colspan="1">27 (6.3)</td><td align="left" rowspan="1" colspan="1">24 (6.7)</td><td align="left" rowspan="1" colspan="1">3 (4.4)</td><td align="char" char="." rowspan="1" colspan="1">0.596</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal tenderness</td><td align="left" rowspan="1" colspan="1">53 (12.4)</td><td align="left" rowspan="1" colspan="1">45 (12.5)</td><td align="left" rowspan="1" colspan="1">8 (11.6)</td><td align="char" char="." rowspan="1" colspan="1">0.834</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Laboratory parameters</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">WBC (10<sup>9</sup>/L)</td><td align="left" rowspan="1" colspan="1">2.2 (1.5,3.9)</td><td align="left" rowspan="1" colspan="1">2.3 (1.5,3.9)</td><td align="left" rowspan="1" colspan="1">1.9 (1.4,4.0)</td><td align="char" char="." rowspan="1" colspan="1">0.342</td></tr><tr><td align="left" rowspan="1" colspan="1">NEU (%) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">61.03&#x000b1;18.34</td><td align="left" rowspan="1" colspan="1">60.06&#x000b1;18.35</td><td align="left" rowspan="1" colspan="1">65.95&#x000b1;17.64</td><td align="char" char="." rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">NEU (10<sup>9</sup> /L)</td><td align="left" rowspan="1" colspan="1">1.2 (0.8,2.4)</td><td align="left" rowspan="1" colspan="1">1.2 (0.8,2.4)</td><td align="left" rowspan="1" colspan="1">1.4 (1.0,2.7)</td><td align="char" char="." rowspan="1" colspan="1">0.181</td></tr><tr><td align="left" rowspan="1" colspan="1">LYM (%) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">29.26&#x000b1;14.16</td><td align="left" rowspan="1" colspan="1">30.58&#x000b1;14.32</td><td align="left" rowspan="1" colspan="1">22.52&#x000b1;11.17</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LYM (10<sup>9</sup>/L)</td><td align="left" rowspan="1" colspan="1">0.6(0.4,1.0)</td><td align="left" rowspan="1" colspan="1">0.6(0.4,1.1)</td><td align="left" rowspan="1" colspan="1">0.5(0.3,0.7)</td><td align="char" char="." rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">MON (%)</td><td align="left" rowspan="1" colspan="1">6.3(3.0,10.7)</td><td align="left" rowspan="1" colspan="1">6.6(3.4,10.9)</td><td align="left" rowspan="1" colspan="1">3.9(1.6,9.0)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">MON (10<sup>9</sup>/L)</td><td align="left" rowspan="1" colspan="1">0.1(0.1,0.3)</td><td align="left" rowspan="1" colspan="1">0.1(0.1,0.3)</td><td align="left" rowspan="1" colspan="1">0.1(0.0,0.2)</td><td align="char" char="." rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">RBC (10<sup>12</sup>/L) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">4.57&#x000b1;0.66</td><td align="left" rowspan="1" colspan="1">4.57&#x000b1;0.60</td><td align="left" rowspan="1" colspan="1">4.52&#x000b1;0.89</td><td align="char" char="." rowspan="1" colspan="1">0.647</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb (g/L) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">138.74&#x000b1;20.28</td><td align="left" rowspan="1" colspan="1">137.98&#x000b1;20.75</td><td align="left" rowspan="1" colspan="1">142.71&#x000b1;17.26</td><td align="char" char="." rowspan="1" colspan="1">0.082</td></tr><tr><td align="left" rowspan="1" colspan="1">PLT (109 /L)</td><td align="left" rowspan="1" colspan="1">55.0(40.0,71.0)</td><td align="left" rowspan="1" colspan="1">56.0(42.0,73.0)</td><td align="left" rowspan="1" colspan="1">41.7(31.0,64.0)</td><td align="char" char="." rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">LDH (U/L)</td><td align="left" rowspan="1" colspan="1">605.5 (384.0,900.0)</td><td align="left" rowspan="1" colspan="1">536.0 (360.0,864.0)</td><td align="left" rowspan="1" colspan="1">900.0 (639.0,1244.0)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CK (U/L)</td><td align="left" rowspan="1" colspan="1">504.0 (184.0,1155.0)</td><td align="left" rowspan="1" colspan="1">455.0 (172.0,985.0)</td><td align="left" rowspan="1" colspan="1">1163.0 (247.0,2000.0)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CK-MB (U/L)</td><td align="left" rowspan="1" colspan="1">23.9 (15.0,38.8)</td><td align="left" rowspan="1" colspan="1">22.6 (14.9,35.1)</td><td align="left" rowspan="1" colspan="1">35.0 (16.0,71.0)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">K (mmol/L) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">3.79&#x000b1;0.55</td><td align="left" rowspan="1" colspan="1">3.74&#x000b1;0.52</td><td align="left" rowspan="1" colspan="1">4.09&#x000b1;0.61</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">NA (mmol/L) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">133.27&#x000b1;5.53</td><td align="left" rowspan="1" colspan="1">133.35&#x000b1;5.39</td><td align="left" rowspan="1" colspan="1">132.78&#x000b1;6.30</td><td align="char" char="." rowspan="1" colspan="1">0.477</td></tr><tr><td align="left" rowspan="1" colspan="1">Cl (mmol/L) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">97.80&#x000b1;5.19</td><td align="left" rowspan="1" colspan="1">97.78&#x000b1;4.98</td><td align="left" rowspan="1" colspan="1">97.89&#x000b1;6.32</td><td align="char" char="." rowspan="1" colspan="1">0.902</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN (mmol/L)</td><td align="left" rowspan="1" colspan="1">5.7 (4.1,8.0)</td><td align="left" rowspan="1" colspan="1">5.2 (3.9,7.3)</td><td align="left" rowspan="1" colspan="1">8.3 (6.1,13.1)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">sCr (&#x003bc;mol/L)</td><td align="left" rowspan="1" colspan="1">72.5 (59.0,95.0)</td><td align="left" rowspan="1" colspan="1">70.0 (58.0,90.0)</td><td align="left" rowspan="1" colspan="1">87.5 (65.0,142.7)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">GLU (mmol/L) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">7.80&#x000b1;4.58</td><td align="left" rowspan="1" colspan="1">7.80&#x000b1;4.64</td><td align="left" rowspan="1" colspan="1">7.85&#x000b1;4.22</td><td align="char" char="." rowspan="1" colspan="1">0.939</td></tr><tr><td align="left" rowspan="1" colspan="1">PT (s)</td><td align="left" rowspan="1" colspan="1">12.3 (11.2,13.5)</td><td align="left" rowspan="1" colspan="1">12.2 (11.2,13.3)</td><td align="left" rowspan="1" colspan="1">12.5 (11.7,14.3)</td><td align="char" char="." rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" rowspan="1" colspan="1">PTA (%) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">100.49&#x000b1;27.41</td><td align="left" rowspan="1" colspan="1">102.10&#x000b1;26.90</td><td align="left" rowspan="1" colspan="1">91.90&#x000b1;28.84</td><td align="char" char="." rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" rowspan="1" colspan="1">APTT (s) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">43.05&#x000b1;16.36</td><td align="left" rowspan="1" colspan="1">40.33&#x000b1;10.88</td><td align="left" rowspan="1" colspan="1">59.38&#x000b1;29.53</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="left" rowspan="1" colspan="1">72.6 (40.0,133.0)</td><td align="left" rowspan="1" colspan="1">67.5 (38.0,122.5)</td><td align="left" rowspan="1" colspan="1">115.8 (67.0,261.0)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="left" rowspan="1" colspan="1">146.0 (71.0,275.1)</td><td align="left" rowspan="1" colspan="1">125.2 (67.0,247.0)</td><td align="left" rowspan="1" colspan="1">416.0 (197.2,793.0)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">TBil (&#x003bc;mol/L)</td><td align="left" rowspan="1" colspan="1">10.1 (7.3,13.3)</td><td align="left" rowspan="1" colspan="1">9.8 (7.2,13.0)</td><td align="left" rowspan="1" colspan="1">12.7 (9.5,23.3)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ALB (g/L) <xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">33.17&#x000b1;5.20</td><td align="left" rowspan="1" colspan="1">33.29&#x000b1;4.98</td><td align="left" rowspan="1" colspan="1">32.34&#x000b1;6.52</td><td align="char" char="." rowspan="1" colspan="1">0.361</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>WBC white blood cell, NEU (%) neutrophil percentage, NEU neutrophil, LYM (%) lymphocyte percentage, LYM lymphocyte, MON (%) monocyte percentage, MON monocyte, RBC red blood cell, Hb hemoglobin, PLT platelet count, LDH lactate dehydrogenase, CK creatinine kinase, CK-MB creatinine kinase myocardial b fraction, K potassium, Na sodium, Cl chloride, BUN Blood urea nitrogen, sCr serum creatinine, GLU glucose, PT prothrombin time, PTA prothrombin activity, APTT activated partial thromboplastin time, ALT alanine aminotransferase, AST aspartate aminotransferase, TB total bilirubin, ALB albumin.</p></fn><fn id="t001fn002"><p><sup>&#x000a7;</sup> P&#x0003c;0.05</p></fn><fn id="t001fn003"><p>* t test was used to compare groups. Mean &#x000b1; standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec014"><title>Manifestation during the early stage of the disease</title><p>Most of the patients visited the hospitals at the early stage of SFTS. They showed moderate fever and their average temperature at admission was 38.9&#x000b1;0.6&#x000b0;C. Body temperature at admission in the survival and mortality groups was comparable (38.9&#x000b1;0.6 vs. 38.9&#x000b1;0.5 &#x000b0;C, p &#x0003e; 0.05). Other major systemic symptoms included headache (29.1%), dizziness (28.2%), myalgia (41.5%) and chills (35.4%). Gastrointestinal symptoms included nausea (46.6%), vomiting (16.3%), diarrhea (18.9%), and bloating (2.6%). Some patients also had respiratory symptoms such as cough (17.5%), sputum (11.4%), and tachypnea (7.7%). Encephalopathy was identified in 109 (25.4%) patients, of which included 57 mortality cases. The incidence of encephalopathy in fatal cases was significantly higher than in those who survived (57/69 (82.6%) vs. 52/360 (14.4%), p &#x0003c; 0.05) (<xref rid="pntd.0007829.t001" ref-type="table">Table 1</xref>). On the other hand, the incidence of headache in the survival group was significantly higher than in the mortality group (31.9% vs. 14.5%, p &#x0003c; 0.05).</p><p>Abnormal physical examination findings at admission included pharyngeal hyperemia (32.9%), flushing (19.4%), abdominal tenderness (12.4%), lymphadenopathy (23.5%), hepatosplenomegaly (6.3%), and hemorrhages (8.6%). There were no significance differences of these findings between the survival and mortality groups.</p></sec><sec id="sec015"><title>Comparison of laboratory parameters in surviving and fatal SFTS cases</title><p>All patients exhibited early leukopenia, thrombocytopenia, elevated liver enzymes, and impairment of myocardial functions. Patients with fatal outcomes had a higher percentage of neutrophils, and lower percentages and absolute counts of lymphocytes, monocytes, and platelets. As shown in <xref rid="pntd.0007829.t001" ref-type="table">Table 1</xref>, the levels of creatine kinase (CK), creatine kinase isozyme (CK-MB), lactate dehydrogenase (LDH), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were significantly increased and APTT was markedly longer in the mortality group compared with the survival group. Interestingly, unlike patients with HFRS, only a small number of patients with SFTS, especially in fatal cases, showed mild renal impairment. Levels of blood urea nitrogen (BUN) and serum creatinine (sCr) in fatal patients were significantly higher than in non-fatal cases (<xref rid="pntd.0007829.t001" ref-type="table">Table 1</xref>). Though the fatal group had a relatively higher concentration of serum potassium and bilirubin (TBil), and lower percentage of prothrombin activity, the levels were still within the normal range.</p></sec><sec id="sec016"><title>Risk factors for fatal outcomes</title><p>Univariable Cox regression analyses revealed that older age, presence of encephalopathy, decreased percentage of lymphocytes, low PTA, elevated percentage of neutrophil, and elevated levels of CK, CK-MB, LDH (ULN), ALT, AST, BUN, sCr, and APTT were risk factors for fatal outcomes. The above variables were used for multivariable Cox regression analyses. The results indicated that low lymphocyte percentage, early-stage encephalopathy, and elevated concentration of serum LDH and BUN were independent risk factors for fatal outcomes. The detailed results of the multivariable analyses are shown in <xref rid="pntd.0007829.t002" ref-type="table">Table 2</xref>.</p><table-wrap id="pntd.0007829.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.t002</object-id><label>Table 2</label><caption><title>Univariable and multivariable Cox regression analyses of features associated with fatal outcomes in patients with SFTS.</title></caption><alternatives><graphic id="pntd.0007829.t002g" xlink:href="pntd.0007829.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="center" colspan="5" rowspan="1">Univariable analysis</th><th align="center" colspan="5" rowspan="1">Multivariable analysis</th></tr><tr><th align="center" rowspan="2" colspan="1">&#x000df;</th><th align="center" rowspan="2" colspan="1">P</th><th align="center" rowspan="2" colspan="1">HR</th><th align="center" colspan="2" rowspan="1">95%CI for HR</th><th align="center" rowspan="2" colspan="1">&#x000df;</th><th align="center" rowspan="2" colspan="1">P</th><th align="center" rowspan="2" colspan="1">HR</th><th align="center" colspan="2" rowspan="1">95%CI for HR</th></tr><tr><th align="center" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th><th align="center" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" char="." rowspan="1" colspan="1">-0.408</td><td align="char" char="." rowspan="1" colspan="1">0.101</td><td align="char" char="." rowspan="1" colspan="1">0.665</td><td align="char" char="." rowspan="1" colspan="1">0.409</td><td align="char" char="." rowspan="1" colspan="1">1.082</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" char="." rowspan="1" colspan="1">0.071</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">1.073</td><td align="char" char="." rowspan="1" colspan="1">1.048</td><td align="char" char="." rowspan="1" colspan="1">1.099</td><td align="char" char="." rowspan="1" colspan="1">0.035</td><td align="char" char="." rowspan="1" colspan="1">0.010</td><td align="char" char="." rowspan="1" colspan="1">1.036</td><td align="char" char="." rowspan="1" colspan="1">1.008</td><td align="char" char="." rowspan="1" colspan="1">1.064</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="char" char="." rowspan="1" colspan="1">-0.279</td><td align="char" char="." rowspan="1" colspan="1">0.314</td><td align="char" char="." rowspan="1" colspan="1">0.757</td><td align="char" char="." rowspan="1" colspan="1">0.440</td><td align="char" char="." rowspan="1" colspan="1">1.302</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Encephalopathy</td><td align="char" char="." rowspan="1" colspan="1">3.012</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">20.330</td><td align="char" char="." rowspan="1" colspan="1">11.091</td><td align="char" char="." rowspan="1" colspan="1">37.265</td><td align="char" char="." rowspan="1" colspan="1">2.567</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">13.028</td><td align="char" char="." rowspan="1" colspan="1">6.771</td><td align="char" char="." rowspan="1" colspan="1">25.068</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (109/L)</td><td align="char" char="." rowspan="1" colspan="1">-0.030</td><td align="char" char="." rowspan="1" colspan="1">0.401</td><td align="char" char="." rowspan="1" colspan="1">0.970</td><td align="char" char="." rowspan="1" colspan="1">0.905</td><td align="char" char="." rowspan="1" colspan="1">1.041</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NEU (%)</td><td align="char" char="." rowspan="1" colspan="1">0.018</td><td align="char" char="." rowspan="1" colspan="1">0.016</td><td align="char" char="." rowspan="1" colspan="1">1.018</td><td align="char" char="." rowspan="1" colspan="1">1.003</td><td align="char" char="." rowspan="1" colspan="1">1.033</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NEU (109/L)</td><td align="char" char="." rowspan="1" colspan="1">0.029</td><td align="char" char="." rowspan="1" colspan="1">0.506</td><td align="char" char="." rowspan="1" colspan="1">1.030</td><td align="char" char="." rowspan="1" colspan="1">0.944</td><td align="char" char="." rowspan="1" colspan="1">1.123</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LYM (%)</td><td align="char" char="." rowspan="1" colspan="1">-0.043</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">0.958</td><td align="char" char="." rowspan="1" colspan="1">0.939</td><td align="char" char="." rowspan="1" colspan="1">0.977</td><td align="char" char="." rowspan="1" colspan="1">-0.038</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">0.963</td><td align="char" char="." rowspan="1" colspan="1">0.943</td><td align="char" char="." rowspan="1" colspan="1">0.983</td></tr><tr><td align="left" rowspan="1" colspan="1">LYM (109/L)</td><td align="char" char="." rowspan="1" colspan="1">-0.257</td><td align="char" char="." rowspan="1" colspan="1">0.181</td><td align="char" char="." rowspan="1" colspan="1">0.773</td><td align="char" char="." rowspan="1" colspan="1">0.531</td><td align="char" char="." rowspan="1" colspan="1">1.127</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MON (%)</td><td align="char" char="." rowspan="1" colspan="1">-0.043</td><td align="char" char="." rowspan="1" colspan="1">0.071</td><td align="char" char="." rowspan="1" colspan="1">0.958</td><td align="char" char="." rowspan="1" colspan="1">0.914</td><td align="char" char="." rowspan="1" colspan="1">1.004</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MON (109/L)</td><td align="char" char="." rowspan="1" colspan="1">-0.005</td><td align="char" char="." rowspan="1" colspan="1">0.751</td><td align="char" char="." rowspan="1" colspan="1">0.995</td><td align="char" char="." rowspan="1" colspan="1">0.968</td><td align="char" char="." rowspan="1" colspan="1">1.024</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RBC (1012/L)</td><td align="char" char="." rowspan="1" colspan="1">-0.110</td><td align="char" char="." rowspan="1" colspan="1">0.560</td><td align="char" char="." rowspan="1" colspan="1">0.896</td><td align="char" char="." rowspan="1" colspan="1">0.619</td><td align="char" char="." rowspan="1" colspan="1">1.297</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hb (g/L)</td><td align="char" char="." rowspan="1" colspan="1">0.010</td><td align="char" char="." rowspan="1" colspan="1">0.080</td><td align="char" char="." rowspan="1" colspan="1">1.010</td><td align="char" char="." rowspan="1" colspan="1">0.999</td><td align="char" char="." rowspan="1" colspan="1">1.022</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PLT (109/L)</td><td align="char" char="." rowspan="1" colspan="1">-0.001</td><td align="char" char="." rowspan="1" colspan="1">0.800</td><td align="char" char="." rowspan="1" colspan="1">0.999</td><td align="char" char="." rowspan="1" colspan="1">0.990</td><td align="char" char="." rowspan="1" colspan="1">1.008</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LDH (U/L)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">1.001</td><td align="char" char="." rowspan="1" colspan="1">1.000</td><td align="char" char="." rowspan="1" colspan="1">1.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CK (U/L)</td><td align="char" char="." rowspan="1" colspan="1">0.000</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">1.000</td><td align="char" char="." rowspan="1" colspan="1">1.000</td><td align="char" char="." rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CK-MB (U/L)</td><td align="char" char="." rowspan="1" colspan="1">0.004</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">1.004</td><td align="char" char="." rowspan="1" colspan="1">1.002</td><td align="char" char="." rowspan="1" colspan="1">1.006</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LDH (ULN)</td><td align="char" char="." rowspan="1" colspan="1">0.554</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">1.741</td><td align="char" char="." rowspan="1" colspan="1">1.407</td><td align="char" char="." rowspan="1" colspan="1">2.154</td><td align="char" char="." rowspan="1" colspan="1">0.323</td><td align="char" char="." rowspan="1" colspan="1">0.004</td><td align="char" char="." rowspan="1" colspan="1">1.381</td><td align="char" char="." rowspan="1" colspan="1">1.111</td><td align="char" char="." rowspan="1" colspan="1">1.718</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN (mmol/L)</td><td align="char" char="." rowspan="1" colspan="1">0.074</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">1.076</td><td align="char" char="." rowspan="1" colspan="1">1.049</td><td align="char" char="." rowspan="1" colspan="1">1.105</td><td align="char" char="." rowspan="1" colspan="1">0.053</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">1.055</td><td align="char" char="." rowspan="1" colspan="1">1.026</td><td align="char" char="." rowspan="1" colspan="1">1.084</td></tr><tr><td align="left" rowspan="1" colspan="1">sCr (&#x003bc;mol/L)</td><td align="char" char="." rowspan="1" colspan="1">0.004</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">1.004</td><td align="char" char="." rowspan="1" colspan="1">1.002</td><td align="char" char="." rowspan="1" colspan="1">1.006</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GLU (mmol/L)</td><td align="char" char="." rowspan="1" colspan="1">-0.003</td><td align="char" char="." rowspan="1" colspan="1">0.923</td><td align="char" char="." rowspan="1" colspan="1">0.997</td><td align="char" char="." rowspan="1" colspan="1">0.935</td><td align="char" char="." rowspan="1" colspan="1">1.063</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PT (s)</td><td align="char" char="." rowspan="1" colspan="1">-0.001</td><td align="char" char="." rowspan="1" colspan="1">0.855</td><td align="char" char="." rowspan="1" colspan="1">0.999</td><td align="char" char="." rowspan="1" colspan="1">0.986</td><td align="char" char="." rowspan="1" colspan="1">1.012</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PTA (%)</td><td align="char" char="." rowspan="1" colspan="1">-0.013</td><td align="char" char="." rowspan="1" colspan="1">0.023</td><td align="char" char="." rowspan="1" colspan="1">0.987</td><td align="char" char="." rowspan="1" colspan="1">0.976</td><td align="char" char="." rowspan="1" colspan="1">0.998</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">APTT (s)</td><td align="char" char="." rowspan="1" colspan="1">0.031</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">1.032</td><td align="char" char="." rowspan="1" colspan="1">1.023</td><td align="char" char="." rowspan="1" colspan="1">1.041</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="char" char="." rowspan="1" colspan="1">0.000</td><td align="char" char="." rowspan="1" colspan="1">0.011</td><td align="char" char="." rowspan="1" colspan="1">1.000</td><td align="char" char="." rowspan="1" colspan="1">1.000</td><td align="char" char="." rowspan="1" colspan="1">1.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">1.001</td><td align="char" char="." rowspan="1" colspan="1">1.001</td><td align="char" char="." rowspan="1" colspan="1">1.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ALB (g/L)</td><td align="char" char="." rowspan="1" colspan="1">-0.033</td><td align="char" char="." rowspan="1" colspan="1">0.266</td><td align="char" char="." rowspan="1" colspan="1">0.968</td><td align="char" char="." rowspan="1" colspan="1">0.913</td><td align="char" char="." rowspan="1" colspan="1">1.026</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>WBC white blood cell, NEU (%) neutrophil percentage, NEU neutrophil, LYM (%) lymphocyte percentage, LYM lymphocyte, MON (%) monocyte percentage, MON monocyte, RBC red blood cell, Hb hemoglobin, PLT platelet count, LDH lactate dehydrogenase, CK creatinine kinase, CK-MB creatinine kinase myocardial b fraction, LDH (ULN) Multiple of the normal upper limit of lactate dehydrogenase, BUN Blood urea nitrogen, sCr serum creatinine, GLU glucose, PT prothrombin time, PTA prothrombin activity, APTT activated partial thromboplastin time, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec017"><title>Prognostic nomogram for mortality risk</title><p>The coefficients obtained from the Cox regression model were used to establish the nomograms for death (<xref ref-type="fig" rid="pntd.0007829.g001">Fig 1</xref>). Each parameter within the variables was assigned a score. By adding up the total score from all the variables and locating it to the total point scale, we could determine the probabilities of death by drawing a vertical line to the total score. The nomograms included all the five risk factors screened by the multivariable Cox analysis: older age, low lymphocyte percentage, early-stage encephalopathy, and elevated serum LDH and BUN levels. Details concerning the point assignment for the nomogram and the prognostic score are shown in <xref rid="pntd.0007829.t003" ref-type="table">Table 3</xref>.</p><fig id="pntd.0007829.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.g001</object-id><label>Fig 1</label><caption><title>SFTS survival rate nomogram.</title><p>To use the nomogram, the value of an individual patient is located on each variable axis, and a line is drawn upward to determine the number of points received for the value of each variable. The sum of these numbers is located on the total point axis, and a line is drawn downward to the survival axes to determine the probability of 7-, 14-, and 28-days survivals. LYM (%) lymphocyte percentage; LDH lactate dehydrogenase; BUN Blood urea nitrogen. *LDH (ULN) Multiple of the normal upper limit of lactate dehydrogenase.</p></caption><graphic xlink:href="pntd.0007829.g001"/></fig><table-wrap id="pntd.0007829.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.t003</object-id><label>Table 3</label><caption><title>Early-stage points of patients with SFTS and predicted survival rate.</title></caption><alternatives><graphic id="pntd.0007829.t003g" xlink:href="pntd.0007829.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Age</th><th align="left" rowspan="2" colspan="1">Points</th><th align="left" rowspan="2" colspan="1">Encephalopathy</th><th align="left" rowspan="2" colspan="1">Points</th><th align="left" rowspan="2" colspan="1">LYM (%)</th><th align="left" rowspan="2" colspan="1">Points</th><th align="left" rowspan="2" colspan="1">BUN (mmol/L)</th><th align="left" rowspan="2" colspan="1">Points</th><th align="left" rowspan="2" colspan="1">LDH (ULN)<xref ref-type="table-fn" rid="t003fn002">*</xref></th><th align="left" rowspan="2" colspan="1">Points</th><th align="center" colspan="6" rowspan="1">Survival rate</th></tr><tr><th align="left" rowspan="1" colspan="1">Total points</th><th align="left" rowspan="1" colspan="1">7 days</th><th align="left" rowspan="1" colspan="1">Total points</th><th align="left" rowspan="1" colspan="1">14 days</th><th align="left" rowspan="1" colspan="1">Total points</th><th align="left" rowspan="1" colspan="1">28 days</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">36</td><td align="char" char="." rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">19</td><td align="char" char="." rowspan="1" colspan="1">0.9</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>LYM (%) lymphocyte percentage; BUN Blood urea nitrogen; LDH lactate dehydrogenase.</p></fn><fn id="t003fn002"><p>* LDH (ULN) Multiple of the normal upper limit of lactate dehydrogenase</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec018"><title>Validation of the prognostic nomogram</title><p>The C-index for the established nomogram to predict the death risk was 0.91 (95% CI: 0.87&#x02013;0.93). ROC curves and calibration plots were performed to validate the predictive accuracy of the nomogram. The 7-, 14-, and 28-days survival ROC results had AUCs of 0.944 (95% CI: 0.920&#x02013;0.968), 0.924 (95% CI: 0.896&#x02013;0.953), and 0.924 (95% CI: 0.895&#x02013;0.952), respectively (Figs <xref ref-type="fig" rid="pntd.0007829.g002">2</xref> and <xref ref-type="fig" rid="pntd.0007829.g003">3</xref> and <xref rid="pntd.0007829.t004" ref-type="table">Table 4</xref>), suggesting a good concordance and a reliable ability.</p><fig id="pntd.0007829.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.g002</object-id><label>Fig 2</label><caption><title>Predictive accuracy of the nomogram model.</title><p>Receiver operating characteristics (ROC) curves of the multivariable logistic regression model for predicting 7-, 14-, and 28-days survivals in patients with SFTS.</p></caption><graphic xlink:href="pntd.0007829.g002"/></fig><fig id="pntd.0007829.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.g003</object-id><label>Fig 3</label><caption><title>Calibration curves of overall survival at 7, 14, and 28 days for the primary cohort.</title><p>Nomogram-predicted probability of survival is plotted on the x-axis, and the actual survival is plotted on the y-axis. Dashed lines along the 45&#x000b0; line through the point of origin represent the perfect calibration models where the predicted probabilities are identical to the actual probabilities. A. Overall survival at 7 days. B. Overall survival at 14 days. C. Overall survival at 28 days.</p></caption><graphic xlink:href="pntd.0007829.g003"/></fig><table-wrap id="pntd.0007829.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.t004</object-id><label>Table 4</label><caption><title>AUC of the ROC curves of the nomogram model.</title></caption><alternatives><graphic id="pntd.0007829.t004g" xlink:href="pntd.0007829.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">AUC</th><th align="center" colspan="2" rowspan="1">95%CI for AUC</th><th align="center" colspan="2" rowspan="1">Goodness of Fit</th></tr><tr><th align="center" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th><th align="center" rowspan="1" colspan="1">LR</th><th align="center" rowspan="1" colspan="1">R<sup>2</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">7-Days</td><td align="char" char="." rowspan="1" colspan="1">0.944</td><td align="char" char="." rowspan="1" colspan="1">0.920</td><td align="char" char="." rowspan="1" colspan="1">0.968</td><td align="char" char="." rowspan="1" colspan="1">116.12</td><td align="char" char="." rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">14-Days</td><td align="char" char="." rowspan="1" colspan="1">0.924</td><td align="char" char="." rowspan="1" colspan="1">0.896</td><td align="char" char="." rowspan="1" colspan="1">0.953</td><td align="char" char="." rowspan="1" colspan="1">208.79</td><td align="char" char="." rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">28-Days</td><td align="char" char="." rowspan="1" colspan="1">0.924</td><td align="char" char="." rowspan="1" colspan="1">0.895</td><td align="char" char="." rowspan="1" colspan="1">0.952</td><td align="char" char="." rowspan="1" colspan="1">213.94</td><td align="char" char="." rowspan="1" colspan="1">0.54</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>AUC: area under the receiver operating characteristics curve.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec019"><title>Prognosis classification of patients with SFTS</title><p>According to the nomogram we established, patients were divided into three levels of death risk: low, moderate, and high. As shown in <xref rid="pntd.0007829.t005" ref-type="table">Table 5</xref>, among the patients with &#x0003c;18 points, only six patients died (2.2%). There were 25 patients with 18&#x02013;26 points who died (24.0%, HR = 11.957). If patients scored points &#x02265;27, the mortality rate was 69.1% (HR = 57.768). The Kaplan-Meier curves showed cumulative mortality in patients with different risk levels in primary cohort. The cumulative mortality was significantly different among the three groups (<xref ref-type="fig" rid="pntd.0007829.g004">Fig 4</xref>).</p><fig id="pntd.0007829.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.g004</object-id><label>Fig 4</label><caption><title>Kaplan-Meier curves of risk stratification for cumulative mortality in the primary cohort of SFTS according to the prognostic scores from the nomogram.</title></caption><graphic xlink:href="pntd.0007829.g004"/></fig><table-wrap id="pntd.0007829.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0007829.t005</object-id><label>Table 5</label><caption><title>Death risk prognosis group according to nomogram score.</title></caption><alternatives><graphic id="pntd.0007829.t005g" xlink:href="pntd.0007829.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Group</th><th align="center" rowspan="2" colspan="1">Score</th><th align="center" rowspan="2" colspan="1">All</th><th align="center" colspan="2" rowspan="1">Non-fatal</th><th align="center" colspan="2" rowspan="1">Fatal</th><th align="center" rowspan="2" colspan="1">HR (95%CI)</th></tr><tr><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">~18</td><td align="center" rowspan="1" colspan="1">270</td><td align="center" rowspan="1" colspan="1">264</td><td align="char" char="." rowspan="1" colspan="1">97.8</td><td align="center" rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">~27</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">79</td><td align="char" char="." rowspan="1" colspan="1">76.0</td><td align="center" rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">24.0</td><td align="center" rowspan="1" colspan="1">11.957 (4.903~29.163)</td></tr><tr><td align="left" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">~40</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">30.9</td><td align="center" rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">69.1</td><td align="center" rowspan="1" colspan="1">57.768 (24.317~137.234)</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">429</td><td align="center" rowspan="1" colspan="1">360</td><td align="char" char="." rowspan="1" colspan="1">83.9</td><td align="center" rowspan="1" colspan="1">69</td><td align="char" char="." rowspan="1" colspan="1">16.1</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><p>SFTS is widely distributed in China, being endemic in more than 20 provinces [<xref rid="pntd.0007829.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0007829.ref008" ref-type="bibr">8</xref>]. The mortality of SFTS ranges from 11.2% to 30%. In addition to China, SFTS has been reported in Korea, Japan, and the United States [<xref rid="pntd.0007829.ref016" ref-type="bibr">16</xref>,<xref rid="pntd.0007829.ref024" ref-type="bibr">24</xref>]. The incidence, clinical manifestations, and mortality of SFTS are similar to those in China, especially in South Korea. There are outbreaks by nosocomial infection, and the mortality is much higher than the rate reported in China [<xref rid="pntd.0007829.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0007829.ref006" ref-type="bibr">6</xref>]. This study aimed to analyze the clinical information of patients with early-stage SFTS and to establish a nomogram for the mortality risk. The resulting nomogram is a simple and practical clinical scoring system, through which we can identify critically ill patients and provide intensive medical intervention for patients as soon as possible to reduce mortality.</p><p>In the present study, 69 patients died (16.1%). Sex was not associated with mortality, but the mean age was significantly higher among those who died, as supported by previous studies [<xref rid="pntd.0007829.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0007829.ref025" ref-type="bibr">25</xref>,<xref rid="pntd.0007829.ref026" ref-type="bibr">26</xref>]. Older patients usually have a higher incidence and duration of comorbidities and poor compensatory organ function, which might explain, at least in part, the higher mortality than that observed in younger patients. The mortality rate of SFTS is high, but the CDC reports contrary results [<xref rid="pntd.0007829.ref027" ref-type="bibr">27</xref>]. The possible reasons for this discrepancy may include: 1) frontline physicians may have insufficient understanding of this disease and fail to diagnose it; and 2) many hospitals are unable to detect SFTSV and cannot make the accurate diagnosis in the first place. Therefore, there is an urgent need to enhance the diagnosis and management of this disease through a comprehensive reporting system, education about SFTS, exploration of the risk factors for death, early identification of critically ill patients, and early intensive medical intervention.</p><p>In addition to systemic symptoms, patients who eventually die show higher frequencies of vomiting, diarrhea, petechia or ecchymosis, and lymphadenopathy [<xref rid="pntd.0007829.ref028" ref-type="bibr">28</xref>&#x02013;<xref rid="pntd.0007829.ref030" ref-type="bibr">30</xref>], but those symptoms and signs were not observed in the present study. On the other hand, we observed that the frequency of encephalopathy in the mortality group was higher than in the survival group, while the frequency of headache was higher in the survival group. The patients in the mortality group might report headache less frequently due to disturbance of consciousness at admission and inability to accurately describe their complaints. Several previous studies reported that manifestations of the central nervous symptom (CNS) such as apathy, hypersomnia, coma, muscle twitching, and hyperspasmia were high-risk factors of death in patients with SFTS [<xref rid="pntd.0007829.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pntd.0007829.ref033" ref-type="bibr">33</xref>]. Park et al. [<xref rid="pntd.0007829.ref034" ref-type="bibr">34</xref>] reported that the CNS manifestations of SFTS, including acute encephalopathy/encephalitis, are common complications of SFTS. Although meningeal inflammation is infrequent in patients with SFTS-associated encephalopathy/encephalitis (SFTSAE), SFTSV is frequently detected in the cerebrospinal fluid (CSF), along with elevated monocyte chemoattractant protein 1 (MCP-1) and IL-8. These findings indicate that direct CNS invasion by the SFTSV with elevated cytokine levels in the CSF may play an important role in the pathogenesis of SFTSAE [<xref rid="pntd.0007829.ref034" ref-type="bibr">34</xref>]. In addition, Masahiko et al. performed an autopsy of a Japanese patient who died of SFTS and found that the rapidly progressive CNS involvement in patient with SFTS might be a result of direct damage caused by infiltration of SFTSV-positive cells into the brain tissues [<xref rid="pntd.0007829.ref035" ref-type="bibr">35</xref>]. Therefore, CNS damage, exhibited as encephalopathy in early stage, is a strong predictor of critical outcomes.</p><p>In the present study, laboratory parameters showed that the levels of platelets and leukocytes were reduced in patients who died, while neutral granulocytopenia was predominant and hemoglobin was normal. On the other hand, the nadir of white blood cells and thrombocytopenia were not significantly related to fatal outcomes [<xref rid="pntd.0007829.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0007829.ref037" ref-type="bibr">37</xref>]. While the level of leukocytes and lymphocytes are both decreased in both groups, their percentages in fatal patients are significantly lower than survivors. These results suggest that the damage or consumption of lymphocytes is more serious in non-surviving patients, indicating more severe acquired immune injury in non-surviving patients. Li et al. [<xref rid="pntd.0007829.ref038" ref-type="bibr">38</xref>] reported that decreased percentage and number of CD4 T cells, including Th1, Th2, and regulatory T cells (Tregs), were associated with an increased severity of SFTS. In addition, increased percentages of Th2, Th17 and Tregs in residual CD4 T cells, as well as skewing of Th17/Treg and Th2/Th1 ratios, may cause poor outcomes in SFTS patients. Hu et al. found that inflammatory mediators remained at high levels when death occurred, while they recovered within 3 weeks in surviving patients, indicating that the occurrence of immunologic injury and inflammatory storm in SFTS patients were associated with the severity of SFTS [<xref rid="pntd.0007829.ref039" ref-type="bibr">39</xref>]. The mortality of SFTS might be related to immunologic injuries [<xref rid="pntd.0007829.ref039" ref-type="bibr">39</xref>,<xref rid="pntd.0007829.ref040" ref-type="bibr">40</xref>].</p><p>In addition to the hematologic system, SFTS can also cause multiple organ damage such as to the myocardium, coagulation function, liver, and kidney. Consistent with previous research [<xref rid="pntd.0007829.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0007829.ref037" ref-type="bibr">37</xref>], we also observed that parameters of myocardial injury such as LDH, CK, CK-MB, and AST levels were elevated in most patients with SFTS who do not survive. The higher the LDH levels, the higher the mortality of SFTS. This result is in accordance with the conclusion of reports by Gai et al. [<xref rid="pntd.0007829.ref041" ref-type="bibr">41</xref>] and Cui et al. [<xref rid="pntd.0007829.ref042" ref-type="bibr">42</xref>]. In the present study, some patients with fatal outcomes exhibited arrhythmia, pulmonary edema, and circulatory failure, which might be the actual cause of death. While the specificity of LDH is limited, its sensitivity is high; therefore, when it increases shortly after infection, along with elevated CK, CK-MB, and AST levels, and especially when cardiac dysrhythmia or dysfunction occurs, it could be a sensitive predictor of fatal outcomes for patients with SFTS.</p><p>Liver damage is a significant manifestation of SFTS [<xref rid="pntd.0007829.ref028" ref-type="bibr">28</xref>,<xref rid="pntd.0007829.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0007829.ref042" ref-type="bibr">42</xref>]. Most of the patients with SFTS had abnormally elevated ALT and AST, but those levels were further higher in the mortality group. We also found that APTT prolongation is common in SFTS patients, especially in the mortality group, with a significantly longer APTT than in survivors. On the other hand, there was no significant jaundice. Furthermore, the ratio of AST/ALT was much higher, suggesting that the AST levels not only indicate acute liver damage, but also reflect the presence of myocardial injury. These results indicate that although patients with SFTS have severe liver inflammation and coagulation abnormalities in the early stage of the disease, liver failure do not occur in all patients who die. While SFTS infection affects the liver function, it is probably not the main cause of death.</p><p>sCr and BUN levels were mildly elevated in the mortality group. The multivariable analysis showed that BUN was an independent risk factor for fatal outcome, as supported by previous studies [<xref rid="pntd.0007829.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0007829.ref043" ref-type="bibr">43</xref>]. The main causes of increased BUN could be high protein diet, decrease in glomerular filtration rate (GFR) and blood volume (hypovolemia), congestive heart failure, gastrointestinal hemorrhage, fever, and increased catabolism. Elevated BUN plays a role in predicting fatal outcome, indicating that BUN reflects the general disease conditions after the onset of SFTS, which include fever, poor nutritional status, increased catabolism, impaired early renal function, and/or insufficient circulating blood volume.</p><p>Based on the univariable and multivariable Cox regression analyses, we established for the first time a mortality risk predictive nomogram for SFTS. Five independent risk factors (older age, early-stage encephalopathy, decreased lymphocyte percentage, and elevated serum concentration of BUN and LDH) were found to be associated with 7-, 14-, and 28 days mortality. The C-index of the prognostic nomogram is 0.91, which shows high value for predicting fatal outcome. The nomogram was applied to the original cohort and the calibration plots showed fair concordance between the nomogram predictions and actual observations for 7-, 14-, and 28-days overall survival. These results strongly support the usefulness of the nomogram in patients with SFTS. Moreover, according to the scoring system, the patients can be divided as low-, moderate-, and high-risk mortality. previous studies attempted scores for predicting the outcomes of SFTF. Wang et al. [<xref rid="pntd.0007829.ref025" ref-type="bibr">25</xref>] established a scoring system using 174 patients and in which the AUC was 0.894. In the system by Xiong et al. [<xref rid="pntd.0007829.ref031" ref-type="bibr">31</xref>], the viral load is included, but not all hospitals in China are able to determine the exact viral load and this scoring system is impractical. In addition, their score relies on a complicated formula. Jia et al. [<xref rid="pntd.0007829.ref043" ref-type="bibr">43</xref>] developed a simple scoring system based on three variables, but it also has a complicated formula. The prominent advantages of our nomogram include that all factors can be obtained through routine examinations, in a timely manner soon after admission, and the score sheet is concise. The nomogram provides fast graphical calculations of complicated formulas to a practical precision. It is practical and intuitional for primary care physicians in the countryside, who are likely to be the first-line doctors to identify this infectious disease. In addition, similar nomograms are available for other infectious diseases such as acute-on-chronic liver failure, bacteremia-urinary tract infections (b-UTI), maternal cytomegalovirus serostatus, and risk of HIV acquisition [<xref rid="pntd.0007829.ref044" ref-type="bibr">44</xref>&#x02013;<xref rid="pntd.0007829.ref047" ref-type="bibr">47</xref>].</p><p>At present, the pathogenesis of SFTS and the exact cause of death are still unclear and there is no specific antiviral treatment available, which is the reason why the mortality rate is still so high. By identifying risk factors for death of SFTS, our work provides useful information for the study of the pathogenesis of this viral infection. We found that age, percentage of lymphocytes, and BUN were host factors. Elevated LDH level and early-stage encephalopathy indicate that the severe injuries to the myocardium and central nervous system by the viral infection are major causes of increased risk of death. In addition, <italic>in vitro</italic> and <italic>in vivo</italic> studies showed that favipiravir was able to inhibit SFTSV virus replication [<xref rid="pntd.0007829.ref048" ref-type="bibr">48</xref>,<xref rid="pntd.0007829.ref049" ref-type="bibr">49</xref>]. We are conducting a clinical trial of favipiravir treatment of SFTS. Classification of the patients according to the severity of the disease at the early stage using the scoring system we established in this study will benefit further research on drug efficacy and side effects.</p><p>Our study has some limitations. First, some patients have given up on further medical treatment because of financial conditions when the disease progressed, and some severely ill patients were lost to follow-up. Second, due to the limited laboratory resources in some primary hospitals, viral load detection of SFTSV could not be conducted at all centers. Third, post-mortem examination was not performed in all cases. Finally, the nomogram we established needs to be improved by external prospective cohorts. For this reason, we are undertaking a prospective study on a larger cohort of SFTS patients hospitalized since September 2018 to validate the predictive value of this model.</p><p>In conclusion, SFTS is broadly distributed in central and northeastern China. The mortality rate is high. The main clinical manifestations are acute fever, thrombocytopenia, and leukopenia, often accompanied multiple organ damage, such as CNS, myocardial, liver, and coagulation function. The severe injuries of the myocardium and central nervous system caused by SFTSV infection are major causes of increased risk of death. Older age, early-stage encephalopathy, decreased lymphocyte percentage, and elevated serum levels of BUN and LDH are independent predictors of death. We established a simple and practical clinical scoring system, through which the patients can be classified as low-, moderate-, and high-risk of mortality. We can identify critically ill patients and provide intensive medical intervention for patients as soon as possible, which may contribute to reducing the mortality of SFTS.</p></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting information</title><supplementary-material content-type="local-data" id="pntd.0007829.s001"><label>S1 Fig</label><caption><title>Distribution map of the five study centers.</title><p>(TIF)</p></caption><media xlink:href="pntd.0007829.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0007829.s002"><label>S1 Checklist</label><caption><title>STROBE checklist.</title><p>(DOC)</p></caption><media xlink:href="pntd.0007829.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pntd.0007829.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>XJ</given-names></name>, <name><surname>Liang</surname><given-names>MF</given-names></name>, <name><surname>Zhang</surname><given-names>SY</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>JD</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Fever with thrombocytopenia associated with a novel bunyavirus in China</article-title>. <source>N Engl J Med</source>
<volume>364</volume>: <fpage>1523</fpage>&#x02013;<lpage>1532</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1010095</pub-id>
<?supplied-pmid 21410387?><pub-id pub-id-type="pmid">21410387</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Zhuang</surname><given-names>L</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Cui</surname><given-names>XM</given-names></name>, <name><surname>Tang</surname><given-names>F</given-names></name>, <name><surname>Hu</surname><given-names>JG</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Transmission of Severe Fever with Thrombocytopenia Syndrome Virus by Haemaphysalis longicornis Ticks, China</article-title>. <source>Emerg Infect Dis</source>
<volume>24</volume>.</mixed-citation></ref><ref id="pntd.0007829.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>UJ</given-names></name>, <name><surname>Kim</surname><given-names>DM</given-names></name>, <name><surname>Kim</surname><given-names>SE</given-names></name>, <name><surname>Kang</surname><given-names>SJ</given-names></name>, <name><surname>Jang</surname><given-names>HC</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Case report: detection of the identical virus in a patient presenting with severe fever with thrombocytopenia syndrome encephalopathy and the tick that bit her</article-title>. <source>BMC Infect Dis</source>
<volume>18</volume>: <fpage>181</fpage>
<pub-id pub-id-type="doi">10.1186/s12879-018-3092-y</pub-id>
<?supplied-pmid 29665796?><pub-id pub-id-type="pmid">29665796</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>LM</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Wen</surname><given-names>HL</given-names></name>, <name><surname>Zhang</surname><given-names>ZT</given-names></name>, <name><surname>Liu</surname><given-names>JW</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Haemaphysalis longicornis Ticks as Reservoir and Vector of Severe Fever with Thrombocytopenia Syndrome Virus in China</article-title>. <source>Emerg Infect Dis</source>
<volume>21</volume>: <fpage>1770</fpage>&#x02013;<lpage>1776</lpage>. <pub-id pub-id-type="doi">10.3201/eid2110.150126</pub-id>
<?supplied-pmid 26402039?><pub-id pub-id-type="pmid">26402039</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>WY</given-names></name>, <name><surname>Choi</surname><given-names>W</given-names></name>, <name><surname>Park</surname><given-names>SW</given-names></name>, <name><surname>Wang</surname><given-names>EB</given-names></name>, <name><surname>Lee</surname><given-names>WJ</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Nosocomial transmission of severe fever with thrombocytopenia syndrome in Korea</article-title>. <source>Clin Infect Dis</source>
<volume>60</volume>: <fpage>1681</fpage>&#x02013;<lpage>1683</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ128</pub-id>
<?supplied-pmid 25694652?><pub-id pub-id-type="pmid">25694652</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>SJ</given-names></name>, <name><surname>Park</surname><given-names>SW</given-names></name>, <name><surname>Bae</surname><given-names>IG</given-names></name>, <name><surname>Kim</surname><given-names>SH</given-names></name>, <name><surname>Ryu</surname><given-names>SY</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Severe Fever with Thrombocytopenia Syndrome in South Korea, 2013&#x02013;2015</article-title>. <source>PLoS Negl Trop Dis</source>
<volume>10</volume>: <fpage>e0005264</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0005264</pub-id>
<?supplied-pmid 28033338?><pub-id pub-id-type="pmid">28033338</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Qu</surname><given-names>X</given-names></name> (<year>2016</year>) <article-title>Investigation on a family clustering occurrence of severe fever with thrombocytopenia syndrome</article-title>. <source>Int J Epidemiol Infect Dis</source>
<volume>43</volume>: <fpage>62</fpage>&#x02013;<lpage>64</lpage>.</mixed-citation></ref><ref id="pntd.0007829.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Yoo</surname><given-names>JR</given-names></name>, <name><surname>Heo</surname><given-names>ST</given-names></name>, <name><surname>Park</surname><given-names>D</given-names></name>, <name><surname>Kim</surname><given-names>H</given-names></name>, <name><surname>Fukuma</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Family Cluster Analysis of Severe Fever with Thrombocytopenia Syndrome Virus Infection in Korea</article-title>. <source>Am J Trop Med Hyg</source>
<volume>95</volume>: <fpage>1351</fpage>&#x02013;<lpage>1357</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.16-0527</pub-id>
<?supplied-pmid 27928083?><pub-id pub-id-type="pmid">27928083</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Gong</surname><given-names>L</given-names></name>, <name><surname>Song</surname><given-names>DD</given-names></name>, <name><surname>Wu</surname><given-names>JB</given-names></name>, <name><surname>Cao</surname><given-names>MH</given-names></name>, <name><surname>Su</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Human-to-human transmissions of severe fever with thrombocytopenia syndrome virus in Anhui province, 2010&#x02013;2017</article-title>. <source>Clin Microbiol Infect</source>
<volume>24</volume>: <fpage>920</fpage>&#x02013;<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2018.03.014</pub-id>
<?supplied-pmid 29559391?><pub-id pub-id-type="pmid">29559391</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Zhan</surname><given-names>J</given-names></name>, <name><surname>Cheng</surname><given-names>J</given-names></name>, <name><surname>Hu</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Pan</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Pathogens and epidemiologic feature of severe fever with thrombocytopenia syndrome in Hubei province, China</article-title>. <source>Virus Res</source>
<volume>232</volume>: <fpage>63</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2017.01.009</pub-id>
<?supplied-pmid 28089865?><pub-id pub-id-type="pmid">28089865</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Lu</surname><given-names>QB</given-names></name>, <name><surname>Xing</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>SF</given-names></name>, <name><surname>Liu</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011&#x02013;17: a prospective observational study</article-title>. <source>Lancet Infect Dis</source>
<volume>18</volume>: <fpage>1127</fpage>&#x02013;<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30293-7</pub-id>
<?supplied-pmid 30054190?><pub-id pub-id-type="pmid">30054190</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Hu</surname><given-names>J</given-names></name>, <name><surname>Cui</surname><given-names>L</given-names></name>, <name><surname>Hong</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Increased Prevalence of Severe Fever with Thrombocytopenia Syndrome in Eastern China Clustered with Multiple Genotypes and Reasserted Virus during 2010&#x02013;2015</article-title>. <source>Sci Rep</source>
<volume>7</volume>: <fpage>6503</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-06853-1</pub-id>
<?supplied-pmid 28747674?><pub-id pub-id-type="pmid">28747674</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Zhan</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Cheng</surname><given-names>J</given-names></name>, <name><surname>Hu</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Current status of severe fever with thrombocytopenia syndrome in China</article-title>. <source>Virol Sin</source>
<volume>32</volume>: <fpage>51</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1007/s12250-016-3931-1</pub-id>
<?supplied-pmid 28251515?><pub-id pub-id-type="pmid">28251515</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Yun</surname><given-names>SM</given-names></name>, <name><surname>Song</surname><given-names>BG</given-names></name>, <name><surname>Choi</surname><given-names>W</given-names></name>, <name><surname>Roh</surname><given-names>JY</given-names></name>, <name><surname>Lee</surname><given-names>YJ</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>First Isolation of Severe Fever with Thrombocytopenia Syndrome Virus from Haemaphysalis longicornis Ticks Collected in Severe Fever with Thrombocytopenia Syndrome Outbreak Areas in the Republic of Korea</article-title>. <source>Vector Borne Zoonotic Dis</source>
<volume>16</volume>: <fpage>66</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1089/vbz.2015.1832</pub-id>
<?supplied-pmid 26745758?><pub-id pub-id-type="pmid">26745758</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Takahashi</surname><given-names>T</given-names></name>, <name><surname>Maeda</surname><given-names>K</given-names></name>, <name><surname>Suzuki</surname><given-names>T</given-names></name>, <name><surname>Ishido</surname><given-names>A</given-names></name>, <name><surname>Shigeoka</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan</article-title>. <source>J Infect Dis</source>
<volume>209</volume>: <fpage>816</fpage>&#x02013;<lpage>827</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit603</pub-id>
<?supplied-pmid 24231186?><pub-id pub-id-type="pmid">24231186</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>McMullan</surname><given-names>LK</given-names></name>, <name><surname>Folk</surname><given-names>SM</given-names></name>, <name><surname>Kelly</surname><given-names>AJ</given-names></name>, <name><surname>MacNeil</surname><given-names>A</given-names></name>, <name><surname>Goldsmith</surname><given-names>CS</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>A new phlebovirus associated with severe febrile illness in Missouri</article-title>. <source>N Engl J Med</source>
<volume>367</volume>: <fpage>834</fpage>&#x02013;<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1203378</pub-id>
<?supplied-pmid 22931317?><pub-id pub-id-type="pmid">22931317</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>J</given-names></name>, <name><surname>Lu</surname><given-names>L</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Ren</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>The changing epidemiological characteristics of severe fever with thrombocytopenia syndrome in China, 2011&#x02013;2016</article-title>. <source>Sci Rep</source>
<volume>7</volume>: <fpage>9236</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-08042-6</pub-id>
<?supplied-pmid 28835633?><pub-id pub-id-type="pmid">28835633</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Touijer</surname><given-names>K</given-names></name>, <name><surname>Scardino</surname><given-names>PT</given-names></name> (<year>2009</year>) <article-title>Nomograms for staging, prognosis, and predicting treatment outcomes</article-title>. <source>Cancer</source>
<volume>115</volume>: <fpage>3107</fpage>&#x02013;<lpage>3111</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.24352</pub-id>
<?supplied-pmid 19544538?><pub-id pub-id-type="pmid">19544538</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Kattan</surname><given-names>MW</given-names></name>, <name><surname>Scardino</surname><given-names>PT</given-names></name> (<year>2007</year>) <article-title>Evidence for the usefulness of nomograms</article-title>. <source>Nat Clin Pract Urol</source>
<volume>4</volume>: <fpage>638</fpage>&#x02013;<lpage>639</lpage>. <pub-id pub-id-type="doi">10.1038/ncpuro0968</pub-id>
<?supplied-pmid 17984994?><pub-id pub-id-type="pmid">17984994</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref020"><label>20</label><mixed-citation publication-type="journal"><collab>Ministry of Health of People's Republic of China</collab> (<year>2011</year>) <article-title>Fever with thrombocytopenia syndrome Prevention Guide (2010 edition)</article-title>. <source>J Clin Infect Dis</source>
<volume>04</volume>: <fpage>193</fpage>&#x02013;<lpage>194</lpage>.</mixed-citation></ref><ref id="pntd.0007829.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Granerod</surname><given-names>J</given-names></name>, <name><surname>Ambrose</surname><given-names>HE</given-names></name>, <name><surname>Davies</surname><given-names>NW</given-names></name>, <name><surname>Clewley</surname><given-names>JP</given-names></name>, <name><surname>Walsh</surname><given-names>AL</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study</article-title>. <source>Lancet Infect Dis</source>
<volume>10</volume>: <fpage>835</fpage>&#x02013;<lpage>844</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(10)70222-X</pub-id>
<?supplied-pmid 20952256?><pub-id pub-id-type="pmid">20952256</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref022"><label>22</label><mixed-citation publication-type="other">Frank E, Harrell J Rms: Regression Modeling Strategies. R Package version 3. 4&#x02013;0. <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=rms">https://CRAN.R-project.org/package=rms</ext-link>. Accessed 17 Jan 2012.</mixed-citation></ref><ref id="pntd.0007829.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Camp</surname><given-names>RL</given-names></name>, <name><surname>Dolled-Filhart</surname><given-names>M</given-names></name>, <name><surname>Rimm</surname><given-names>DL</given-names></name> (<year>2004</year>) <article-title>X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization</article-title>. <source>Clin Cancer Res</source>
<volume>10</volume>: <fpage>7252</fpage>&#x02013;<lpage>7259</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0713</pub-id>
<?supplied-pmid 15534099?><pub-id pub-id-type="pmid">15534099</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Muehlenbachs</surname><given-names>A</given-names></name>, <name><surname>Fata</surname><given-names>CR</given-names></name>, <name><surname>Lambert</surname><given-names>AJ</given-names></name>, <name><surname>Paddock</surname><given-names>CD</given-names></name>, <name><surname>Velez</surname><given-names>JO</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Heartland virus-associated death in tennessee</article-title>. <source>Clin Infect Dis</source>
<volume>59</volume>: <fpage>845</fpage>&#x02013;<lpage>850</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu434</pub-id>
<?supplied-pmid 24917656?><pub-id pub-id-type="pmid">24917656</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Zou</surname><given-names>Z</given-names></name>, <name><surname>Hou</surname><given-names>C</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Jiang</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Score risk model for predicting severe fever with thrombocytopenia syndrome mortality</article-title>. <source>BMC Infect Dis</source>
<volume>17</volume>: <fpage>42</fpage>
<pub-id pub-id-type="doi">10.1186/s12879-016-2111-0</pub-id>
<?supplied-pmid 28061758?><pub-id pub-id-type="pmid">28061758</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>MM</given-names></name>, <name><surname>Lei</surname><given-names>XY</given-names></name>, <name><surname>Yu</surname><given-names>XJ</given-names></name> (<year>2016</year>) <article-title>Meta-analysis of the clinical and laboratory parameters of SFTS patients in China</article-title>. <source>Virol J</source>
<volume>13</volume>: <fpage>198</fpage>
<pub-id pub-id-type="doi">10.1186/s12985-016-0661-9</pub-id>
<?supplied-pmid 27899121?><pub-id pub-id-type="pmid">27899121</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Zhou</surname><given-names>H</given-names></name>, <name><surname>Mu</surname><given-names>D</given-names></name>, <name><surname>Yin</surname><given-names>W</given-names></name>, <name><surname>Yu</surname><given-names>H</given-names></name> (<year>2015</year>) [<article-title>Epidemiological analysis on severe fever with thrombocytopenia syndrome under the national surveillance data from 2011 to 2014, China</article-title>]. <source>Zhonghua Liu Xing Bing Xue Za Zhi</source>
<volume>36</volume>: <fpage>598</fpage>&#x02013;<lpage>602</lpage>. <?supplied-pmid 26564632?><pub-id pub-id-type="pmid">26564632</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Song</surname><given-names>R</given-names></name>, <name><surname>Shen</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Yu</surname><given-names>X</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Multiple organ injury of severe fever with thrombocytopenia syndrome</article-title>. <source>Infect Dis Inform</source>
<volume>4</volume>: <fpage>234</fpage>&#x02013;<lpage>237</lpage>.</mixed-citation></ref><ref id="pntd.0007829.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Lyu</surname><given-names>Y</given-names></name>, <name><surname>Jiang</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Estimation of the incidence of severe fever with thrombocytopenia syndrome in high endemic areas in China: an inpatient-based retrospective study</article-title>. <source>BMC Infect Dis</source>
<volume>18</volume>: <fpage>66</fpage>
<pub-id pub-id-type="doi">10.1186/s12879-018-2970-7</pub-id>
<?supplied-pmid 29402229?><pub-id pub-id-type="pmid">29402229</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>ZH</given-names></name>, <name><surname>Qin</surname><given-names>XC</given-names></name>, <name><surname>Song</surname><given-names>R</given-names></name>, <name><surname>Shen</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>XP</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Co-circulation of multiple hemorrhagic fever diseases with distinct clinical characteristics in Dandong, China</article-title>. <source>PLoS One</source>
<volume>9</volume>: <fpage>e89896</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0089896</pub-id>
<?supplied-pmid 24587107?><pub-id pub-id-type="pmid">24587107</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Xiong</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Xiong</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>A simple and practical score model for predicting the mortality of severe fever with thrombocytopenia syndrome patients</article-title>. <source>Medicine (Baltimore)</source>
<volume>95</volume>: <fpage>e5708</fpage>.<pub-id pub-id-type="pmid">28033271</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Deng</surname><given-names>B</given-names></name>, <name><surname>Zhou</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Zhu</surname><given-names>Y</given-names></name>, <name><surname>Han</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in Northeast China</article-title>. <source>PLoS One</source>
<volume>8</volume>: <fpage>e80802</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0080802</pub-id>
<?supplied-pmid 24236203?><pub-id pub-id-type="pmid">24236203</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Shin</surname><given-names>J</given-names></name>, <name><surname>Kwon</surname><given-names>D</given-names></name>, <name><surname>Youn</surname><given-names>SK</given-names></name>, <name><surname>Park</surname><given-names>JH</given-names></name> (<year>2015</year>) <article-title>Characteristics and Factors Associated with Death among Patients Hospitalized for Severe Fever with Thrombocytopenia Syndrome, South Korea, 2013</article-title>. <source>Emerg Infect Dis</source>
<volume>21</volume>: <fpage>1704</fpage>&#x02013;<lpage>1710</lpage>. <pub-id pub-id-type="doi">10.3201/eid2110.141928</pub-id>
<?supplied-pmid 26402575?><pub-id pub-id-type="pmid">26402575</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>SY</given-names></name>, <name><surname>Kwon</surname><given-names>JS</given-names></name>, <name><surname>Kim</surname><given-names>JY</given-names></name>, <name><surname>Kim</surname><given-names>SM</given-names></name>, <name><surname>Jang</surname><given-names>YR</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Severe fever with thrombocytopenia syndrome-associated encephalopathy/encephalitis</article-title>. <source>Clin Microbiol Infect</source>
<volume>24</volume>: <fpage>432.e431</fpage>&#x02013;<lpage>432.e434</lpage>.<pub-id pub-id-type="pmid">28899841</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Kaneko</surname><given-names>M</given-names></name>, <name><surname>Shikata</surname><given-names>H</given-names></name>, <name><surname>Matsukage</surname><given-names>S</given-names></name>, <name><surname>Maruta</surname><given-names>M</given-names></name>, <name><surname>Shinomiya</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>A patient with severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis-associated involvement of the central nervous system</article-title>. <source>J Infect Chemother</source>
<volume>24</volume>: <fpage>292</fpage>&#x02013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiac.2017.10.016</pub-id>
<?supplied-pmid 29138019?><pub-id pub-id-type="pmid">29138019</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Jia</surname><given-names>B</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Huang</surname><given-names>R</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Risk factors associated with fatality of severe fever with thrombocytopenia syndrome: a meta-analysis</article-title>. <source>Oncotarget</source>
<volume>8</volume>: <fpage>89119</fpage>&#x02013;<lpage>89129</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.19163</pub-id>
<?supplied-pmid 29179504?><pub-id pub-id-type="pmid">29179504</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Feng</surname><given-names>Z</given-names></name>, <name><surname>Geng</surname><given-names>D</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Dynamic changes of laboratory parameters and peripheral blood lymphocyte subsets in severe fever with thrombocytopenia syndrome patients</article-title>. <source>Int J Infect Dis</source>
<volume>58</volume>: <fpage>45</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2017.02.017</pub-id>
<?supplied-pmid 28249810?><pub-id pub-id-type="pmid">28249810</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>MM</given-names></name>, <name><surname>Zhang</surname><given-names>WJ</given-names></name>, <name><surname>Weng</surname><given-names>XF</given-names></name>, <name><surname>Li</surname><given-names>MY</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>CD4 T cell loss and Th2 and Th17 bias are associated with the severity of severe fever with thrombocytopenia syndrome (SFTS)</article-title>. <source>Clin Immunol</source>
<volume>195</volume>: <fpage>8</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2018.07.009</pub-id>
<?supplied-pmid 30036637?><pub-id pub-id-type="pmid">30036637</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>LF</given-names></name>, <name><surname>Wu</surname><given-names>T</given-names></name>, <name><surname>Wang</surname><given-names>B</given-names></name>, <name><surname>Wei</surname><given-names>YY</given-names></name>, <name><surname>Kong</surname><given-names>QX</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>The Regulation of Seventeen Inflammatory Mediators are Associated with Patient Outcomes in Severe Fever with Thrombocytopenia Syndrome</article-title>. <source>Sci Rep</source>
<volume>8</volume>: <fpage>159</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-18616-z</pub-id>
<?supplied-pmid 29317732?><pub-id pub-id-type="pmid">29317732</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>MM</given-names></name>, <name><surname>Lei</surname><given-names>XY</given-names></name>, <name><surname>Yu</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>JZ</given-names></name>, <name><surname>Yu</surname><given-names>XJ</given-names></name> (<year>2017</year>) <article-title>Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome</article-title>. <source>Virol J</source>
<volume>14</volume>: <fpage>6</fpage>
<pub-id pub-id-type="doi">10.1186/s12985-016-0677-1</pub-id>
<?supplied-pmid 28086978?><pub-id pub-id-type="pmid">28086978</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Gai</surname><given-names>ZT</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Liang</surname><given-names>MF</given-names></name>, <name><surname>Jin</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients</article-title>. <source>J Infect Dis</source>
<volume>206</volume>: <fpage>1095</fpage>&#x02013;<lpage>1102</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis472</pub-id>
<?supplied-pmid 22850122?><pub-id pub-id-type="pmid">22850122</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Cui</surname><given-names>N</given-names></name>, <name><surname>Liu</surname><given-names>R</given-names></name>, <name><surname>Lu</surname><given-names>QB</given-names></name>, <name><surname>Wang</surname><given-names>LY</given-names></name>, <name><surname>Qin</surname><given-names>SL</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Severe fever with thrombocytopenia syndrome bunyavirus-related human encephalitis</article-title>. <source>J Infect</source>
<volume>70</volume>: <fpage>52</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2014.08.001</pub-id>
<?supplied-pmid 25135231?><pub-id pub-id-type="pmid">25135231</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Jia</surname><given-names>B</given-names></name>, <name><surname>Yan</surname><given-names>X</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>G</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>A scoring model for predicting prognosis of patients with severe fever with thrombocytopenia syndrome</article-title>. <source>PLoS Negl Trop Dis</source>
<volume>11</volume>: <fpage>e0005909</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0005909</pub-id>
<?supplied-pmid 28934195?><pub-id pub-id-type="pmid">28934195</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Gong</surname><given-names>J</given-names></name>, <name><surname>Zhou</surname><given-names>W</given-names></name>, <name><surname>Xiao</surname><given-names>C</given-names></name>, <name><surname>Jie</surname><given-names>Y</given-names></name>, <name><surname>Zhu</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>A nomogram for predicting prognostic value of inflammatory biomarkers in patients with acute-on-chronic liver failure</article-title>. <source>Clin Chim Acta</source>
<volume>478</volume>: <fpage>7</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2017.12.018</pub-id>
<?supplied-pmid 29247632?><pub-id pub-id-type="pmid">29247632</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Lalueza</surname><given-names>A</given-names></name>, <name><surname>Sanz-Trepiana</surname><given-names>L</given-names></name>, <name><surname>Bermejo</surname><given-names>N</given-names></name>, <name><surname>Yaiza</surname><given-names>B</given-names></name>, <name><surname>Morales-Cartagena</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Risk factors for bacteremia in urinary tract infections attended in the emergency department</article-title>. <source>Intern Emerg Med</source>
<volume>13</volume>: <fpage>41</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/s11739-016-1576-6</pub-id>
<?supplied-pmid 27864665?><pub-id pub-id-type="pmid">27864665</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Kuessel</surname><given-names>L</given-names></name>, <name><surname>Husslein</surname><given-names>H</given-names></name>, <name><surname>Marschalek</surname><given-names>J</given-names></name>, <name><surname>Brunner</surname><given-names>J</given-names></name>, <name><surname>Ristl</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Prediction of Maternal Cytomegalovirus Serostatus in Early Pregnancy: A Retrospective Analysis in Western Europe</article-title>. <source>PLoS One</source>
<volume>10</volume>: <fpage>e0145470</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0145470</pub-id>
<?supplied-pmid 26693714?><pub-id pub-id-type="pmid">26693714</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Kagaayi</surname><given-names>J</given-names></name>, <name><surname>Gray</surname><given-names>RH</given-names></name>, <name><surname>Whalen</surname><given-names>C</given-names></name>, <name><surname>Fu</surname><given-names>P</given-names></name>, <name><surname>Neuhauser</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Indices to measure risk of HIV acquisition in Rakai, Uganda</article-title>. <source>PLoS One</source>
<volume>9</volume>: <fpage>e92015</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0092015</pub-id>
<?supplied-pmid 24704778?><pub-id pub-id-type="pmid">24704778</pub-id></mixed-citation></ref><ref id="pntd.0007829.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Gowen</surname><given-names>BB</given-names></name>, <name><surname>Westover</surname><given-names>JB</given-names></name>, <name><surname>Miao</surname><given-names>J</given-names></name>, <name><surname>Van Wettere</surname><given-names>AJ</given-names></name>, <name><surname>Rigas</surname><given-names>JD</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir</article-title>. <source>J Virol</source>
<volume>91</volume>.</mixed-citation></ref><ref id="pntd.0007829.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Tani</surname><given-names>H</given-names></name>, <name><surname>Fukuma</surname><given-names>A</given-names></name>, <name><surname>Fukushi</surname><given-names>S</given-names></name>, <name><surname>Taniguchi</surname><given-names>S</given-names></name>, <name><surname>Yoshikawa</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus</article-title>. <source>mSphere</source>
<volume>1</volume>.</mixed-citation></ref></ref-list></back></article>